Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 20.02.2025 · 392 (8) · 777-787
DOI: 10.1056/nejmoa2409183 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 20.02.2025. Verfasst von EMPA-KIDNEY Collaborative Group und 41 weiteren Autor:innen. Beteiligte Einrichtung: Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Ox…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, NIHR Oxford Biomedical Research Centre, Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
- University Clinic of Würzburg, Würzburg, Germany.
- Duke Clinical Research Institute, Durham, North Carolina, US.
- Boehringer Ingelheim International, Germany.
- Fifth Department of Medicine, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
- University of Utah, Salt Lake City, US.
ORCID-Profile: William G Herrington, David Preiss, Xavier Rossello, Katherine R Tuttle, Martin J Landray
Förderung
- Medical Research Council
- NIHR Oxford Biomedical Research Centre
- Eli Lilly and Company
- Boehringer Ingelheim
- Health Data Research UK
- British Heart Foundation
Zitieren
APA
EMPA-KIDNEY Collaborative Group, Herrington, W. G., Staplin, N., Agrawal, N., Wanner, C., Green, J. B., Hauske, S. J., Emberson, J. R., Preiss, D., Judge, P., Zhu, D., Dayanandan, R., Arimoto, R., Mayne, K. J., Ng, S. Y. A., Sammons, E., Hill, M., Stevens, W., Wallendszus, K., …, & EMPA-KIDNEY Collaborative Group (2025). Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 392(8), 777-787. https://doi.org/10.1056/nejmoa2409183
Vancouver
EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, et al. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2025;392(8):777-787. doi:10.1056/nejmoa2409183
BibTeX
@article{EMPAKIDNEYCollaborativeGroup2025,
author = {EMPA-KIDNEY Collaborative Group, EMPA-KIDNEY Collaborative Group and Herrington, William G and Staplin, Natalie and Agrawal, Nikita and Wanner, Christoph and Green, Jennifer B and Hauske, Sibylle J and Emberson, Jonathan R and Preiss, David and Judge, Parminder and Zhu, Doreen and Dayanandan, Rejive and Arimoto, Ryoki and Mayne, Kaitlin J and Ng, Sarah Y A and Sammons, Emily and Hill, Michael and Stevens, Will and Wallendszus, Karl and Brenner, Susanne and Cheung, Alfred K and Liu, Zhi-Hong and Li, Jing and Hooi, Lai Seong and Liu, Wen and Kadowaki, Takashi and Nangaku, Masaomi and Levin, Adeer and Cherney, David Z I and Maggioni, Aldo P and Pontremoli, Roberto and Deo, Rajat and Goto, Shinya and Rossello, Xavier and Tuttle, Katherine R and Steubl, Dominik and Massey, Dan and Brueckmann, Martina and Landray, Martin J and Baigent, Colin and Haynes, Richard and EMPA-KIDNEY Collaborative Group, EMPA-KIDNEY Collaborative Group},
title = {Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {8},
pages = {777--787},
doi = {10.1056/nejmoa2409183}
}
EUVIMED